[{"from": "human", "value": "Describe this molecule. [C][C][=C][Branch2][Branch1][=C][C][Branch2][Ring2][O][C][=Branch1][Branch2][=C][Branch1][Ring2][N][Ring1][=Branch1][N][C][=Branch1][C][=O][O][C][C][N][Branch1][Ring2][C][Ring1][Ring2][C][Branch1][=Branch2][C][=C][C][=C][C][=C][Ring1][=Branch1][C][=C][C][=C][C][=C][Ring1][=Branch1][C][=C][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N+1][=Branch1][C][=O][O-1][C][=Branch1][C][=O][O][C][Branch1][C][C][C]"}, {"from": "gpt", "value": "The molecule is a dihydropyridine calcium channel blocker. It is marketed by Daiichi-Sankyo pharmaceuticals, Inc. in Japan.  It has a gradual onset of action and produces a long-lasting decrease in blood pressure, with only a small increase in heart rate, unlike some other calcium channel blockers. It is currently being studied for post-ischemic stroke management."}]